Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of ...

Alicia Morgans, MD, explains how the ARACOG trial showed higher cognitive decline with enzalutamide vs darolutamide in ...

Explore why some patients with multiple myeloma miss stem cell transplant, spotlighting age, race and socioeconomic barriers, ...

Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor and how ...

The FDA has allowed the launch of a phase 2 study of MT027, an allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Community oncologists play an important role in expanding access to clinical trials. Patel discusses the value of offering ...

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively ...

The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival ...

Rusfertide was approved by the FDA 1 for adults with polycythemia who require phlebotomy, based on results from the phase 3 ...

Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back ...

Adding stereotactic body radiation therapy (SBRT) or surgery directed at every known metastasis to first-line systemic ...